Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tc 99m tilmanocept imaging vs CD206 expression in rheumatoid arthritis
2018-003418-41Phase 2Unknown
- Sponsor
- Navidea Biopharmaceuticals, Inc.
- Start
- Nov 2019
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of technetium tc 99m tilmanocept in rheumatoid arthritis (RA), sponsored by Navidea Biopharmaceuticals, Inc. Primary endpoint: Primary. Status: unknown.
02
Drugs
technetium tc 99m tilmanocept
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2018-003418-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003418-41.